Bristol Myers Squibb (CELG-RI) Total Debt Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) Total Debt Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -3.40% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 9.03% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 52.27% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -57.33% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -5.50% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 6.99% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.27% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.26% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 6.19% |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | -18.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.21% |
| Mar 31, 2026 | -6.56% |
| Dec 31, 2025 | -12.37% |
| Sep 30, 2025 | -1.56% |
| Jun 30, 2025 | -3.28% |
| Mar 31, 2025 | -10.72% |
| Dec 31, 2024 | 20.71% |
| Sep 30, 2024 | 32.31% |
| Jun 30, 2024 | 47.26% |
| Mar 31, 2024 | 47.18% |
| Dec 31, 2023 | -1.32% |
| Sep 30, 2023 | -8.29% |
| Jun 30, 2023 | -10.42% |
| Mar 31, 2023 | -27.62% |
| Dec 31, 2022 | -3.00% |
| Sep 30, 2022 | -17.19% |
| Jun 30, 2022 | -11.74% |
| Mar 31, 2022 | 12.94% |
| Dec 31, 2021 | -12.08% |
| Sep 30, 2021 | 2.72% |